Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers
Source abstract
Abstract
Dendrimers represents a novel class of macromolecules, which are derived from branches upon branches type structural design. Dendrimers are emerging as promising drug-delivery molecule because of their extraordinary properties including membrane interaction, monodispersity, well-defined size, shape and molecular weight, etc. Drugs interact with dendrimers in three ways; (a) physical encapsulation, (b) electrostatic interactions, and (c) covalent conjugations. Due to compact, globular structure and availability of interior cavity spaces and multiple surface functional groups, drug molecules can be encapsulated both in the interior of the dendrimers (physical encapsulation) as well as attached to the surface functional groups (covalent conjugations).
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Chemical Synthesis and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmaceutical Nanotechnology Research Laboratory, ISF College of Pharmacy, Moga, Punjab, India
National Institute of Pharmaceutical Education and Research (NIPER Raebareli), Raebareli, Uttar Pradesh, India
Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A & M Health Science Center, Texas A & M University, Kingsville, TX, USA
School of Pharmaceutical Sciences, Rajiv Gandhi Technical University, Bhopal, Madhya Pradesh, India
References (58)
Show source-provided references
1. 10.1016/j.ijpharm.2013.08.03710.1016/j.ijpharm.2013.08.037 ↗
2. 10.3390/polym204059610.3390/polym2040596 ↗
3. 10.1039/c4tb00171k10.1039/c4tb00171k ↗
4. Daraee H · Artif Cells Nanomed Biotechnol · 2014 · 17 · 1
5. 10.3109/10731199.2010.49457810.3109/10731199.2010.494578 ↗
6. 10.2174/138920021131405000510.2174/1389200211314050005 ↗
7. 10.1021/cr020010d10.1021/cr020010d ↗
8. 10.1016/S1359-6446(04)03276-310.1016/S1359-6446(04)03276-3 ↗
9. 10.1016/j.ijpharm.2010.04.00210.1016/j.ijpharm.2010.04.002 ↗
10. 10.1016/j.colsurfb.2014.11.00410.1016/j.colsurfb.2014.11.004 ↗
11. Howell BA, Fan D. 2009. Poly(amidoamine) dendrimer-supported organoplatinum antitumour agents. Proceedings of the Royal Society of London A: Mathematical, Physical and Engineering Sciences, 2009.10.1098/rspa.2009.0359 ↗
12. 10.1016/j.colsurfb.2014.09.02410.1016/j.colsurfb.2014.09.024 ↗
13. 10.1016/j.nano.2004.11.00910.1016/j.nano.2004.11.009 ↗
14. Jain K, Jain NK. 2014a. Dendrimer: A 21st century nanobiopolymer. Pharmabiz; [cited 2015 Oct 7]. Available from: http://www.pharmabiz.com/ArticleDetails.aspx?aid=81282&sid=21
15. 10.1166/jnn.2014.867710.1166/jnn.2014.8677 ↗
16. Jain K, Jain NK. 2015. Dendrimers as Nanobiopolymers in Cancer ChemoTherapy: Nanobiomedicine. New Delhi: Studium Press, pp. 65–90.
17. 10.1007/s11051-013-1888-710.1007/s11051-013-1888-7 ↗
18. 10.1007/s11051-013-2003-910.1007/s11051-013-2003-9 ↗
19. 10.1016/j.ejpb.2014.03.01510.1016/j.ejpb.2014.03.015 ↗
20. 10.1016/j.biomaterials.2012.02.03310.1016/j.biomaterials.2012.02.033 ↗
21. 10.1016/j.ijpharm.2010.04.02710.1016/j.ijpharm.2010.04.027 ↗
22. 10.1016/j.coph.2014.01.00610.1016/j.coph.2014.01.006 ↗
23. 10.1016/j.nano.2014.11.00810.1016/j.nano.2014.11.008 ↗
24. 10.1128/AAC.04213-1410.1128/AAC.04213-14 ↗
25. Kaminskas LM · Mol Pharm · 2014 · 31 · 343
26. 10.1016/j.biomaterials.2009.06.02610.1016/j.biomaterials.2009.06.026 ↗
27. 10.1021/ja00113a00510.1021/ja00113a005 ↗
28. 10.1016/j.progpolymsci.2013.07.00510.1016/j.progpolymsci.2013.07.005 ↗
29. 10.1016/j.nano.2010.10.01010.1016/j.nano.2010.10.010 ↗
30. Klajnert B · Acta Biochimica Polonica · 2000 · 48 · 19910.18388/abp.2001_5127 ↗
31. Kozub P · Bratisl Lek Listy · 2011 · 112 · 390
32. 10.1016/j.jconrel.2007.06.01210.1016/j.jconrel.2007.06.012 ↗
33. 10.1016/j.jconrel.2015.09.04310.1016/j.jconrel.2015.09.043 ↗
34. Li T · ACS Appl Mater Interfaces · 2015
35. 10.1016/S1461-5347(99)00203-510.1016/S1461-5347(99)00203-5 ↗
36. 10.1038/nrc107410.1038/nrc1074 ↗
37. 10.4103/0975-7406.13096510.4103/0975-7406.130965 ↗
38. 10.1021/cr900174j10.1021/cr900174j ↗
39. Mehra NK · 2014
40. 10.1016/j.drudis.2015.01.00610.1016/j.drudis.2015.01.006 ↗
41. 10.1039/a809106d10.1039/a809106d ↗
42. 10.1016/j.drudis.2010.01.00910.1016/j.drudis.2010.01.009 ↗
43. 10.1016/S0378-5173(99)00463-910.1016/S0378-5173(99)00463-9 ↗
44. Mishra I. · J Drug Deliv Therapeutics · 2011 · 1 · 70
45. 10.1016/j.coph.2006.05.00410.1016/j.coph.2006.05.004 ↗
46. 10.1016/j.ejps.2009.07.00810.1016/j.ejps.2009.07.008 ↗
47. 10.1166/jnn.2015.980810.1166/jnn.2015.9808 ↗
48. 10.1016/j.jconrel.2003.07.00110.1016/j.jconrel.2003.07.001 ↗
49. 10.1166/jnn.2015.962010.1166/jnn.2015.9620 ↗
50. 10.1016/j.addr.2005.09.01410.1016/j.addr.2005.09.014 ↗
51. 10.1080/09205063.2015.109502310.1080/09205063.2015.1095023 ↗
52. 10.1088/0957-4484/19/29/29510210.1088/0957-4484/19/29/295102 ↗
53. 10.1016/j.ejpb.2008.09.02310.1016/j.ejpb.2008.09.023 ↗
54. 10.1016/j.progpolymsci.2005.01.00710.1016/j.progpolymsci.2005.01.007 ↗
55. Turnbull WB · J. Biotechnol · 2002 · 90 · 231
56. 10.2147/IJN.S8730710.2147/IJN.S87307 ↗
57. 10.1016/j.addr.2008.02.01210.1016/j.addr.2008.02.012 ↗
58. 10.1021/la701968y10.1021/la701968y ↗